The octanol/water distribution coefficients of ardisilloside-I and its metabolites, and their permeation characteristics across Caco-2 cell monolayer

Wei-yu Cao, Bin Feng, Li-fei Cheng, Ying Wang, Ji Wang and Xiao-juan Wang*

Abstract

Background: Ardipusilloside-I (ADS-I) is a triterpenoid saponin extracted from Chinese medicinal herb Ardisiapussil A. DC. Previous studies have demonstrated the potent anti-tumor activities of ADS-I both in vitro and in vivo, and its main metabolites (M1 and M2) from human intestinal bacteria. However, the physicochemical properties and intestinal permeation rate of ADS-I and its metabolites are not understood. In this study, the octanol/water distribution coefficients (logP) of ADS-I and metabolites were investigated using standard shake flask technique, and their permeability properties was investigated across Caco-2 cells monolayer.

Results: The logP of ADS-I, M1 and M2 was $-0.01$, $0.95 \pm 0.04$, $1.57 \pm 0.11$, respectively. The $P_{\text{app}}$ values of ADS-I, M1 and M2 (in $10 \mu$mol/L) across Caco-2 cell monolayers from the apical (AP) to basolateral (BL) direction were $1.88 \pm 0.21 \times 10^{-6} \text{ cm} \cdot \text{s}^{-1}$, $4.30 \pm 0.43 \times 10^{-6} \text{ cm} \cdot \text{s}^{-1}$, $4.74 \pm 0.47 \times 10^{-6} \text{ cm} \cdot \text{s}^{-1}$, respectively.

Conclusion: Our data indicated that ADS-I has the poorer intestinal absorption than its metabolites (M1 and M2) in these experimental systems, suggesting that the metabolites of ADS-I may be the predominant products absorbed by the intestine when ADS-I is administered orally.

Keywords: Ardipusilloside-I, Metabolites, LogP, Caco-2 cell monolayers, Intestinal absorption

Background

Ardipusilloside-I (ADS-I) [1] is a major bioactive triterpenoid saponin isolated from Chinese medicinal herb Ardisiapussil A. DC (Mysinaceae). The anti-tumor activity of this compound was first reported by Dr. Wang’s group [2], followed by many preclinical studies, showing that ADS-I induces tumor cell apoptosis and inhibits tumor cell growth, invasion and metastasis both in vitro and in vivo [3–6]. Pharmacokinetic study of ADS-I in rats shows that this compound has a poor intestinal absorption and the oral bioavailability [7]. Recently, we have shown that ADS-I could be mainly metabolized by human intestinal bacteria to metabolite M1 and M2 as shown in Fig. 1, in which the main metabolic pathway is deglycosylation of ADS-I through stepwise cleavage of sugar moieties [8]. These findings imply that these metabolites of ADS-I may be the primary active substances for its inhibitory activity against the growth of the tumor in vivo after oral administration, which however remains unknown. It has been known that the biological activities of drugs depend not only on their chemical structures, but also on their degree of lipophilic and membrane permeation that facilitate them across the cell membrane [9]. Although a previous study has revealed the poor intestinal absorption as well as a low oral bioavailability of ADS-I [7], the oral pharmacokinetic properties of ADS-I and its metabolites in humans have not investigated of yet. Evidence in literature indicates that deglycosylation...
of ginsenoside by intestinal bacteria to deglycosylated metabolites results in enhancing the permeability of the intestine, better adsorption into systemic circulation and exerting pharmacological effects of the ginsenoside [10–12]. Thus, we speculated that the deglycosylation of ADS-I to the metabolites (M1 and M2) might mediate the intestinal absorption of ADS-I for increased oral bioavailability.

Lipophilicity, commonly expressed as octanol/water distribution coefficient (log P), has been considered as one important measurement of drug physicochemical parameters in drug discovery process to predict the pharmacokinetic properties and intestinal absorption of a drug [13, 14]. Caco-2 cell monolayer has been widely accepted as a standard in vitro model for prediction of drug absorption across human intestine and for mechanistic studies of intestinal drug transport since these cells show morphological and functional similarities to human small intestinal epithelial cells [15–17]. The objective of this study was designed to measure the logP of ADS-I and its metabolites using standard shake flask technique, and their permeability properties using Caco-2 cells monolayer. Thus, we could determine whether the products of ADS-I biotransformation by human intestinal bacteria played a role in the membrane permeability of ADS-I in human intestine.

Results and discussion

LogP of ADS-I and its metabolites in octanol/water

The LogP of ADS-I and its metabolites were determined by using standard shake flask method and HPLC-ELSD technique. The logarithm of logP values of ADS-I and its metabolites were shown in Table 1, indicating that the logP values of ADS-I, M1 and M2 were −0.01, 0.95 ± 0.04, 1.57 ± 0.11 respectively. According to a previous study [18], the value of logP from one to three suggests that the drug is easily absorbed by the intestine, and below zero poorly absorbed. Thus, our experiment results indicated that ADS-I was difficult or less to be absorbed, whereas M2 had the highest absorption. Furthermore, the data also showed that there was a correlation between molecular weight and lipophilicity of ADS-I and its metabolites. As a matter of fact, the absorption extent of these three compounds was negatively correlated with their molecular polarity and molecular weight. Indeed, the larger the molecular polarity and molecular weight of a compound, the more difficulty it is absorbed [19, 20]. ADS-I has the highest polarity and molecular weight compared to M1 and M2, the lower logP value of ADS-I suggests that this compound has a poor absorption in human intestine after oral administration. These results were in agreement with the low oral bioavailability of ADS-I in rats as reported previously [7], and may suggest that these metabolites may have better absorption than ADS-I.

The permeation characteristics of ADS-I and its metabolites across Caco-2 cell monolayer

Cytotoxicity assay

The viability of cells was measured using MTT assay to evaluate the cytotoxicity of ADS-I and its metabolites (M1, M2) in Caco-2 cells prior to transport experiments.

Table 1 The octanol/water partition coefficients (logP) of ADS-I and its metabolites in phosphate-buffers (pH = 7.4)

| ADS-I and its metabolites | MW (g/mol) | Log P (Mean ± SD) |
|--------------------------|------------|-------------------|
| ADS-I                    | 1074       | −0.01             |
| M1                       | 912        | 0.95 ± 0.04       |
| M2                       | 766        | 1.57 ± 0.11       |

Date are presented as mean ± SD (n = 3)
Generally, cell viability of more than 90% indicated that the compounds at the stated concentrations were non-toxic to the cells [21]. As shown in Fig. 2, ADS-I, M1 and M2 at 0–10 µmol/L were nontoxic to the Caco-2 cells after incubation for 4 h. Therefore, 2, 5 and 10 µmol/L of each compound was used for two-way transport experiments.

**Characters of Caco-2 cell monolayer**

In order to confirm if the cells in culture formed a monolayer, the TEER values of the Caco-2 cell monolayer were measured at 5, 7, 9, 13, 17, 21 days after seeding, respectively. As shown in Fig. 3, the Caco-2 cell monolayer was completely formed on day 21 with TEER values above 400 Ω cm² and was used for the transport experiments.

In addition, electron microscope revealed the intact tight junctions in the Caco-2 cell monolayer (Fig. 4). Thus, the Caco-2 cell monolayer model established herein was validated for the permeation experiment.

**Two-way transport of ADS-I and its metabolites across Caco-2 cell monolayer**

The permeability change of ADS-I, M1, or M2 across the Caco-2 cell monolayer at different concentrations from AP to BL direction was shown in Fig. 5, and the accumulated transfer amounts of ADS-I, M1 or M2 increased with a prolonged time of incubation as illustrated in Fig. 5a–c. With the same concentration, the flux amounts of M1 and M2 in AP to BL direction were similar, and both were greater than that of ADS-I (Fig. 5d). As shown in Fig. 6, the $P_{\text{app}}$ value of ADS-I (10 µmol/L) was $1.88 \pm 0.21 \times 10^{-6}$ cm·s⁻¹ for AP to BL direction, and was $0.69 \pm 0.15 \times 10^{-6}$ cm·s⁻¹ for BL to AP direction in 120 min, which was considered to have a poor permeability and absorption rate similar to in vivo [7]. However, with stepwise removal of glycosyl groups in the metabolites (M1 and M2), the $P_{\text{app}}$ values of these compounds increased and were higher than those of ADS-I across the Caco-2 cell monolayer in both directions. The $P_{\text{app}}$ values of M1 (10 µmol/L) in the direction of AP - BL and BL - AP were $4.30 \pm 0.43 \times 10^{-6}$ cm·s⁻¹ and $1.76 \pm 0.26 \times 10^{-6}$ cm·s⁻¹ respectively, and of M2 (10 µmol/L) were $4.74 \pm 0.47 \times 10^{-6}$ cm·s⁻¹ and $2.12 \pm 0.23 \times 10^{-6}$ cm·s⁻¹ respectively. These data suggested that metabolites M1 and M2 were easier to be absorbed than ADS-I by the intestine.

The $P_{\text{app}}$ values of ADS-I, M1 or M2 at different concentrations across the Caco-2 cell monolayer in both directions were shown in Table 2, indicating that the $P_{\text{app}}$ values of these compounds gradually decreased with the increase of their concentration respectively. According to the formula (“The two-way transport experiment” section), the transport amounts of ΔQ increased along with Δt at the same concentration ($C_0$), but the increased speed of ΔQ became slower along with the Δt, which meant that the value of ΔQ/Δt relatively decreased, thus the apparent permeability coefficient ($P_{\text{app}}$) was also reduced. We inferred that the transport of ADS-I, M1 and M2 across the Caco-2 cell monolayer partially depend on their concentration, and some carrier might participate in the process of transportation. Besides, the $P_{\text{app}}$ values of ADS-I and its metabolites (M1 and M2) in AP to BL direction were greater than that in BL to AP direction across the Caco-2 cell monolayer, and efflux ratio (ER) were all 0.3–0.6. These data suggested that ADS-I and its metabolites (M1 and M2) could be absorbed across intestinal epithelial cells in a passive absorption pattern, and the transport processes of these
Fig. 4 Caco-2 cell morphology. a the 2nd day; b the 7th day; c the 21st day

Fig. 5 Change of accumulated amount of a different concentrations of ADS-I, b different concentration of M1, c different concentration of M2, d ADS-I, M1, M2 (10 µmol/L) across Caco-2 cell monolayer from AP to BL direction. Date represent the mean ± SD from three replicates
compounds might not be the substrate of apical efflux transporters.

It has been known that compounds with $P_{\text{app}}$ values less than $2.0 \times 10^{-6}$ cm·s$^{-1}$ are considered to have a low absorption (0–20 %), while those with $P_{\text{app}}$ values between $2.0 \times 10^{-6}$ cm·s$^{-1}$ and $10 \times 10^{-6}$ cm·s$^{-1}$ are considered to have a moderate absorption (20–70 %), and those with $P_{\text{app}}$ values of higher than $10 \times 10^{-6}$ cm·s$^{-1}$ are considered to have a high absorption (70–100 %) [22]. In this study, the transport of the major metabolites (M1, M2) of ADS-I was compared with the parent compound ADS-I in the same system, and showed that ADS-I is a poorly absorbed compound, M1 and M2 belong to the moderately absorbed compound.

**Structure-intestinal permeability relationship**

Physicochemical characters, such as log P, log D and polar surface area, are generally measured for the prediction of drug permeability. To study the structure-intestinal permeability relationship, $P_{\text{app}}$ values of ADS-I and its metabolites (M1 and M2) across Caco-2 cell monolayer were compared with their logP and molecular weight. In Fig. 7a, the $P_{\text{app}}$ values of ADS-I and its metabolites (M1 and M2) transported from apical to basolateral direction ($C_0 10 \mu$M) were plotted as a function of their molecular weight, with stepwise removal of glycosyl groups in the metabolites (M1 and M2), the $P_{\text{app}}$ values of these compounds increased and were higher than the parent compound ADS-I. Figure 7b showed the relationship between $P_{\text{app}}$ and logP of ADS-I and its metabolites (M1 and M2), the $P_{\text{app}}$ (AP to BL direction) values increased with an increase of LogP. These findings indicated that ADS-I and its metabolites (M1 and M2) across Caco-2 cell monolayer were well correlated with their logP and

**Table 2 The $P_{\text{app}}$ values of ADS-I, M1 and M2 at different concentrations across the Caco-2 cell monolayer in both directions in 120 min**

| Compound | Concentration (µmol/L) | $P_{\text{app}}/10^{-6}$ cm·s$^{-1}$ | Efflux ratio |
|----------|------------------------|-------------------------------|--------------|
|          | AP→BL | BL→AP | AP→BL | BL→AP |
| ADS-I    | 2      | 6.66±1.32 2.50±0.53 | 0.38         |
|          | 5      | 3.10±0.33 1.66±0.24 | 0.54         |
|          | 10     | 1.88±0.21 0.69±0.15 | 0.37         |
| M1       | 2      | 9.13±1.65 3.14±0.58 | 0.34         |
|          | 5      | 6.07±0.74 3.45±0.67 | 0.57         |
|          | 10     | 4.30±0.43 1.76±0.26 | 0.41         |
| M2       | 2      | 10.48±1.21 4.53±0.57 | 0.43         |
|          | 5      | 6.76±0.85 2.60±0.43 | 0.38         |
|          | 10     | 4.74±0.47 2.12±0.23 | 0.45         |

Date are presented as mean ± SD (n = 3). **P < 0.01 compared to the control group (ADS-I).
molecular weight, and metabolites M1 and M2 exhibited higher permeability absorption than ADS-I.

**Conclusion**

In this study, the octanol/water distribution coefficients (logP) and membrane permeability properties of ADS-I and its metabolites (M1, M2) were investigated to predict their intestinal absorption in human. Our data suggest that ADS-I has a poor intestinal absorption in human after oral administration. Metabolites (M1, M2) of ADS-I, biotransformed by human intestinal bacteria, exhibited a moderate absorption as well as higher permeability than ADS-I in the following decreasing order: M2 > M1 > ADS-I. These results may suggest that these metabolites may have better absorption than ADS-I, and thus could be the major substances in vivo for inhibitory activities against the growth of tumor after oral administration of ADS-I. In summary, the present results provide useful information to predict the oral bioavailability of ADS-I and its metabolites for the further clinical studies of ADS-I.

**Methods**

**Chemicals and reagents**

ADS-I and its metabolites M1, M2 (purity > 95 %) were provided by Dr. X.-J. Wang at the Department of Pharmacy, School of Stomatology, the Fourth Military Medical University (Xi’an, China). Ginsenoside Re (purity > 93.7 %) was purchased from the National Institute for Food and Drug Control (Beijing, China), 6-well-Transwell plates (insert diameter 24 mm, pore size 0.4 μm, membrane growth area 4.67 cm²) and 96-well plates from Corning Costar (Cambridge, MA, USA), Millicell-ERS system from Millipore Corporation (Bedford, OH, USA), Dulbecco’s Modified Eagle’s medium (DMEM) and fetal bovine serum (FBS) from HyClone Laboratories (Logan, UT, USA), HPLC grade acetonitrile and methanol from Fisher Scientific (Pittsburgh, PA, USA), and Penicillin–streptomycin and 0.25 % trypsin–EDTA solutions from Solarbio (Beijing, China). Other reagents were of analytical purity.

**Determination of Log P of ADS-I metabolites by HPLC–ELSD**

**HPLC–ELSD instrumentation and chromatographic conditions**

ADS-I and its metabolites (M1, M2) concentrations in two phases were quantified using a LC-20A high performance liquid chromatograph (Shimadzu Corporation, Kyoto, Japan) equipped with a Alltech type 3300 evaporative light-scattering detector (Alltech Associates, Deerfield, USA). A Diamonsil C18 (2) column (4.6 × 250 mm, 5 μm) from Diamonsil Technologies (Beijing, China) was used for all the compound separations, and the column temperature was maintained at 25 °C. The mobile phase consisted of 25 % (A) ultra-pure water and 75 % (B) methanol using an isocratic elution. The flow rate was 1 mL/min, and the injection volume was 10 μL. The ELSD was set to a probe temperature at 60 °C, a gain of 1 and the nebulizer gas nitrogen at a flow of 2.0 L/min.

The liner regression equation for ADS-I was $y = 1.9726x + 4.6654$ ($r = 0.9995$), with a good linearity over the range from 0.1002 to 0.9018 mg/mL, $y = 1.8255x + 4.8093$ ($r = 0.9993$) for M1 with a good linearity over the range from 0.1018 to 0.9162 mg/mL, and $y = 1.8006x + 4.8211$ ($r = 0.9992$) for M2 with a good linearity over the range from 0.1010 to 0.9090 mg/mL.

**LogP of ADS-I and its metabolites with a shake flask method**

Prior to the distribution experiment, octanol and phosphate buffer (10 mM, pH 7.4) were mutually saturated at room temperature. ADS-I and its metabolites (M1, M2) were dissolved in DMSO at final concentration of 20 mg/mL, and a volume of 50 μL compound in DMSO solution was added to the octanol/phosphate buffer (1:1, v/v) system. After vortex mixing, the mixtures were orbital shaken for 48 h at 37 °C, and consequently the phases were separated. The solution with two phases were then centrifuged at 13,000 rpm min⁻¹ for 10 min. The concentration of ADS-I and metabolites (M1, M2) in both the phosphate buffer and n-octanol after the shaking was determined by using HPLC-ELSD as described above.

**Data analysis**

The experiments measured logP was calculated using the following equation: $\log P = \log \frac{C_o}{C_w}$ where $C_o$ was the concentration of a compound in the n-octanol phase, $C_w$ is the concentration of the compound in the phosphate buffer phase.

**The permeation characteristics of ADS-I and its metabolites across Caco-2 cell monolayer**

**Cell culture**

The human colon Caco-2 cells were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China), and were cultured in DMEM with 10 % FBS (inactivation at 56 °C for 30 min), 1 % NEAA and 1 % antibiotics (100 IU/ml penicillin and 100 μg/ml streptomycin in a humidified atmosphere of 5 % CO₂ at 37 °C).

**Cytotoxicity assay**

The cytotoxicity of ADS-I and its metabolites (M1, M2) against Caco-2 cells was evaluated by MTT assay. In brief, 100 μL of Caco-2 cell suspension (2 × 10⁴ cells/mL)
per well was seeded in 96-well plates, followed by 24 h incubation (37 °C, 5 % CO₂). ADS-I and its metabolites (M1, M2) were dissolved in DMSO (<1 %) and diluted in DMEM. A volume of 100 μL compounds solution was added to each well and made the final concentrations were 5, 10, 20, 50, 100 μM, respectively. After 4 h incubation, 20 μL of 5 mg/mL MTT was added to each well and incubated for another 4 h. Then the medium was removed and cells were dissolved in 150 μL DMSO with gentle shaking for 10 min, and the optical density (OD) was measured with an ELX800 reader (Bio-Tek instruments, Inc., Winooski, VT, USA) at 490 nm. Untreated cells were used as controls. The doses of a compound with survival rate higher than 90 % were considered non-cytotoxicity.

The two-way transport experiment

For transport experiments, Caco-2 cells were seeded on the rat tail collagen-coated 6-wells Transwell plates (insert diameter 24 mm, pore size 0.4μm, membrane growth area 4.67 cm²) at a density of 1 x 10⁵ cells/cm² and incubated for 19–21 days. The medium was changed every 2 days. The integrity and transportation ability of the Caco-2 cell monolayer was examined by measuring the transepithelial electrical resistance (TEER) of filter-grown cell monolayer with millicell-ERS equipment. Only a monolayer with a TEER value of more than 400 Ω cm² was used for the trans epithelial transport experiments.

The transport of ADS-I and its metabolites across Caco-2 monolayer was investigated as previously described [25, 26]. Before the transport experiment, cells were washed three times with warm HBSS (pH 7.4, 37 °C). Cell monolayer was then incubated for 30 min at 37 °C in the transport buffer. To measure the apical (AP)-to-basolated (BL) permeability, 0.5 mL of the transport buffer containing different concentrations (2, 5, 10 μM) of ADS-I, M1, or M2 was added to AP side of the transwell insert, and 1.5 mL of the HBSS was added to the BL chamber. The plates were incubated in an orbital shaker at 37 °C, 50 rpm/min. To assess the drugs transport from AP to BL, after incubation for 30, 60, 90 or 120 min, a volume of 200 μL aliquot was collected from BL side, followed by immediately being replenished with an equal volume of blank HBSS. For the measurement of BL to AP transport, 1.5 mL of the transport buffer containing different concentrations (2, 5, 10 μM) of ADS-I, M1, or M2 was added to the BL side, and 0.5 mL of the HBSS to AP side. A volume of 200 μL aliquot was harvested from AP side at time intervals of 30, 60, 90 and 120 min respectively, and immediately replaced with the same volume of blank HBSS. The samples were frozen immediately and stored at −80 °C before analysis by UHPLC–MS.

In the Caco-2 cell model, the rate of transport was calculated based on the amount transported vs. time curve using linear regression. The apparent permeability (P_app) as an expression of the absorption rate constant was calculated using the following equation,

$$ P_{app} = \Delta Q / \Delta t / A \times C_0 $$

where $P_{app}$ was the apparent permeability coefficient (cm/s), $\Delta Q / \Delta t$ (μmol/s) represented the appearance rate of the test compound on the receiver side, $A$ (4.67 cm²) is the surface area of the filter membrane and $C_0$ (μmol/L) was the initial concentration in the donor chamber. The efflux ratio (Re) was determined by calculating the ratio of $P_{app}$ (B→A) versus $P_{app}$ (A→B) as the following equation,

$$ Re = P_{app}(B→A) / P_{app}(A→B) $$

Sample preparation for UHPLC–ESI–MS/MS assay

A sample (200 μL) from either cellular absorption or transport experiments was mixed with 20 μL methanol containing the internal standard (ginsenoside Re, 0.498 μg/mL). The mixture was vortexed for 60 s. Then after centrifugation at 10,000 x g for 10 min, 5 μL of supernatant was then injected into the LC/MS system. Also, 200 μL of standard solutions containing different concentrations of ADS-I, M1 or M2 was processed in the same way as above. The calibration curves for ADS-I, M1 or M2 were generated by plotting the peak area ratios of the analyses to the internal standard versus the concentrations by least-square linear regression.

UHPLC–MS analysis

UHPLC-MS analysis was performed using an Agilent 1290 Infinity ultra-high performance liquid chromatography (UHPLC) and 6460 type triple quadrupole (QQQ) mass spectrometer equipped with electrospray ion source (ESI) and Mass Hunter working software version B.04.10 (Agilent Technologies, California, USA). A Poroshell 120 EC C₁₈ column (2.1 × 100 mm, 2.7 μm) from Agilent Technologies was used as an analytical column and the column temperature was maintained at 25 °C. The isocratic mobile phase consisted of 40 % acetonitrile and 60 % H₂O at a flow rate of 0.4 mL/min. Quantification was determined using multiple reactions monitoring model, and the operating parameters were optimized as follows: drying gas (N₂) flow rate, 10.0 L/min; drying gas temperature, 350 °C; nebulizer, 45 psi; capillary, 3500 V; fragmentor voltage, 150 V; sheath gas temperature, 350 °C; sheath gas flow rate, 11 L/min. The precursor-product ion pairs used in MRM mode were: m/z 1073.5 → 927.3 for ADS-I, m/z 911.3 → 765.4 for M1, m/z 765.4 → 603.1 for M2, 945.5 → 475.3 for Ginsenoside Re as an internal standard.
The sensitivity of UHPLC-MS/MS analysis was first evaluated for drug quantification. The regression equation for the standard curve were as follow: y = 1.7226x + 0.1239 (r = 0.9995) for ADS-I with the range of 0.061–0.980 μg/mL and the lower limit of quantification was 10 ng/mL; y = 1.4379x + 0.0417 (r = 0.9993) for M1 with the range of 0.064–1.020 μg/mL and the lower limit of quantification was 8 ng/mL; y = 1.2802x + 0.0579 (r = 0.9987) for M2 with the range of 0.063–1.000 μg/mL and the lower limit of quantification was 6 ng/mL.

**Statistical analysis**

Data were expressed as means ± standard derivation (SD). Statistical analysis was performed using the statistical software SPSS16.0 (SPSS Inc., Chicago, IL, USA). Student’s t test was used to analyze statistical differences between groups. P < 0.05 was considered statistically significant.

**Authors’ contributions**

XJW and BF conceived and designed the experiments; WYC, LFC, YW and JW performed the experiments and helped with the data analysis; and WYC, BF wrote the paper. All authors read and approved the final manuscript.

**Acknowledgements**

This work was supported by Shaanxi Province Administration of Traditional Chinese Medicine Foundation of China (No.13-2Y041).

**Competing interests**

The authors declare that they have no competing interests.

**Received:** 3 March 2016  **Accepted:** 26 April 2016  **Published online:** 05 May 2016

**References**

1. Zhang QH, Wang XJ, Miu ZC, Feng R (1993) Chemical research on ardidusilloside. Acta Pharm. Sin 28:673–678
2. Liang KM, Wang SW, Wang XJ (2001) Inhibitory effect on of ardisipusilloside I purified from Ardisia pusilla I. Acta Pharm. Sin 28:673–678
3. Xiong Jian, Cheng Guang, Tang Hai-Feng, Zhen Hai-ning, Zhang Xiang (2009) Ardisipusilloside I induces apoptosis in human glioblastoma cells through a caspase-8-independent FasL/Fas-signaling pathway. J Envr Toxicol Pharmacol 27:264–270
4. Zhang Yan-min, You-le Qu, Zhang Jie, Xiao-juan W (2010) Ardisipusilloside I purified from Ardisia pusilla competitively binds VEGFR and induces apoptosis in NCI-H460 cells. Phytomedicine 17:519–526
5. Lou Lian-qing, Ye Wei-wei, Chen Yong-xin, Shuang Wu, Jin Lin-zheng, He Jin-ke, Tao Xing-fei, Zhu Jing-hong, Chen Xiang-yi, Deng An-mei, Wang Jin-he (2012) Ardisipusilloside inhibits survival, invasion and metastasis of human hepatocellular carcinoma cells. Phytomedicine 19:603–608
6. Tao Xi, Wang PX, Yang XJ, Yao HP, Liu J, Cao YS (2005) Inhibitory effect of Ardisipusilloside-I on Lewis pulmonary carcinoma and hepatocarcinoma SMCC-7721. J Chin Med Mater 28:574–577
7. Wang XJ, Cui H, Wang R, Huan ML, Zhang BL, Zhang WD, Teng ZH, Gan HQ, Zhou SY, Gu Y (2012) Metabolism and pharmacokinetic study of Ardisipusilloside I in rats. Planta Med 78:565–574
8. Cao Wei-Yu, Wang Ya-Nan, Wang Peng-Yuan, Lei Wan, Feng Bin, Wang Xiao-jian (2015) Ardisipusilloside-I metabolites from human intestinal bacteria and their antimutagen activity. Molecules 20:20569–20581
9. Soumyajit M, Shidhar D, Ashim KM (2004) Membrane transporter/receptor-targeted produrg design: strategies for human and veterinary drug development. Adv Drug Delivery Rev 56:1437–1452
10. Odani T, Tanizawa H, Takino Y (1983) Studies on the absorption, distribution, excretion and metabolism of Ginseng saponins. IV. Decomposition of ginsenoside-Rg1 and Rbl in the digestive tract of rats. Chem Pharm Bull 31:3691–3697
11. Qian T, Jiang ZH, Cai ZW (2006) High-performance liquid chromatography coupled with tandem mass spectrometry applied for metabolic study of ginsenoside Rb1 on rats. Anal Biochem 352:87–96
12. Ruan Jian-Qing, Weng-im Leong Ru, Yan Yi-tao Wang (2010) Characterization of metabolism and in vitro permeability study of notoginsenoside R1 from Radix notoginseng. J Agric Food Chem 58:570–5776
13. Tetko Igor V, Varbanov Hristo P, Galanski Markus, Talmaciu Mona, Platts James A, Ravera Mauro, Gabano Elisabetta (2016) Prediction of log P for Pt(II) and Pt(IV) complexes: comparison of statistical and quantum-chemistry based approaches. J Inorg Biochem 156:1–13
14. Piniko Tomasz, Grudziens Monika, Taciak Przemyslaw Pawel, Mazurek Aleksander Pawel (2016) Cytosine basicity, solvation, log P, and log D theoretical determinations as tool for bioavailability prediction. J Moli Graph Model 63:15–21
15. Pinto M, Robine-Leon S, Appay MD, Kedinger M, Triadou N, Dussaule E, Lacroix B, Simon-Assmann P, Haffen K, Fogh J, Zweibaum A (1983) Enterocyte-like differentiation and polarization of the human colon carcinoma cell line Caco-2 in culture. Biol Cell 47:323–330
16. Grassel E, Pinto M, Dussaule E, Zweibaum A, Desjeux JF (1984) Epithelial properties of human colonic carcinoma cell line Caco-2: electrical parameters. Am J Physiol 247:260–267
17. Borlak J, Zwadlo C (2005) Expression of drug-metabolizing enzymes, nuclear transcription factors and ABC transporters in Caco-2 cells. Xenobiotica 33:927–943
18. Lin JZ, Zou L, Fu CM, Zhang DK, Wang P, Qm L (2013) Octanol/water partition coefficient and absorption kinetics of salidroside and tyrosol in rat intestine. Chin Tradi Pat Med 35:483–486
19. Yang Yan-Fang, Wei Xu, Song Wei, Ye Min, Yang Xiu-Wei (2015) Transport of twelve coumarins from Angelicae Pubescentis Radix across a MDCK-pHMDR cell monolayer-an in vitro model for blood-brain barrier permeability. Molecules 20(11719–11732
20. Yang XW, Huong X, Ma L, Wu Q, Xu W (2010) The intestinal permeability of neoglignans from the seeds of Myristica fragrans in the Caco-2 cell monolayer model. Planta Med 76:1587–1591
21. Wahlang B, Pavar YB, Bansal AK (2011) Identification of permeability-related hurdles in oral delivery of curcumin using the Caco-2 cell model. Eur J Pharm Biopharm 77:275–282
22. Gao J, Hugger E, Beck-Westermeyer MS (2000) Current protocols in pharmacology estimation of intestinal mucosal permeation of compounds using Caco-2 cell monolayers. John Wiley Sons Inc, New York
23. Heshmati Nasim, Wagner B, Cheng X, Schol T, Kansy M, Eisenbrand G, Fricke G (2013) Physicochemical characterization and in vitro permeation of an indirubin derivative. Euro J Pharm Sci 50:467–475
24. Monikawa Go, Suzuka Chihiro, Shojo Atsushi, Shibusawa Yoichi, Yanagida Akio (2016) High-throughput determination of octanol/water partition coefficients using a shake-flask method and novel two-phase solvent system. J PharmBiomed Anal 117:338–344
25. Zheng Mengkai, Zhou Huifen, Wan Haitong, Yu-Lin C, H Y (2015) Effects of herbal drugs in Mahuang decoction and their main components on intestinal transport characteristics of Ephedra alkaloids evaluated by a Caco-2 cell monolayer model. J Ethnopharmacol 164:22–29
26. Liu L, Guo L, Zhao C, Wu X, Wang R, Liu C (2015) Characterization of the intestinal absorption of seven flavonoids from the flowers of Trollius chinensis using the Caco-2 cell monolayer model. PLoS One 19(3):1–18